ANNX - Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting | Benzinga
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients
ANX005 Has Potential to be the First Targeted Therapy Approved for the Treatment of GBS
BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the Company will have several presentations on the Company's ANX005 Guillain-Barré Syndrome (GBS) program at the 2024 Peripheral Nerve Society (PNS) Annual Meeting being held June 22-25, 2024 at the Palais des congrès de Montréal in Montréal, Canada. Pivotal Phase 3 clinical results of ANX005 in GBS, including further analyses of early and durable treatment effects on measures important to patients and the medical community, will be highlighted as part of a plenary clinical presentation, as well as discussed in an Annexon sponsored lunch symposium, a flash oral presentation, and two poster presentations.
Details of the presentations are as follows:
Oral Presentation: "Design of a Phase 3 Study Evaluating ANX005 in Patients with Guillain-Barré Syndrome"
- Abstract #: O 442
- Session: The Richard A.C. Hughes Symposium: Clinical Highlights
- Presenter: Dr. Quazi Deen Mohammad, National Institute of Neuroscience, Bangladesh
- Date/Time: Tuesday, June 25, 2024, 4:59 – 5:12 p.m. EDT
- Location: Main Plenary Hall
Annexon Lunch Symposium: "Annexon Biosciences Breaking New Ground in the GBS Treatment Landscape"
- Presenters: Dr. David Cornblath, Johns Hopkins University School of Medicine, USA; Dr. Bart Jacobs, Erasmus MC, Netherlands; Dr. Luis Querol, Hospital de la Santa Creu i Sant Pau, Spain; Dr. Jeff Allen, University of Minnesota, USA; Lisa Butler, GBS|CIDP Foundation International, USA
- Time and date: Tuesday, June 25, 2024, 1:15 – 2:15 p.m. EDT
- Location: Room 710b
Flash Oral Presentation: "Comparative Efficacy: ANX005's Potential Advantage over Intravenous Immunoglobulin in Guillain-Barré Syndrome"
- Abstract #: 83890
- Session: Inflammatory Neuropathy Consortium (INC) Concurrent SIG – INC Flash Presentations
- Presenter: Dr. Henk-André Kroon, Annexon Biosciences, USA
- Time and date: Sunday, June 23, 2024, 4:25 – 4:30 p.m. EDT
- Location: Room 517d
Poster Presentation: "Coexistence of Acute Motor Axonal Neuropathy and Acute Inflammatory Demyelinating Polyneuropathy in Guillain-Barré Syndrome"
- Abstract #: P 238
- Session: Poster Session II
- Presenter: Dr. Henk-André Kroon, Annexon Biosciences, USA
- Date/Time: Monday, June 24, 2024, 2:15 – ...